J&J's Janssen nabs new indication, full approval for cancer drug Rybrevant
Johnson & Johnson’s Janssen on Friday earned an FDA approval for its cancer drug Rybrevant (amivantamab-vmjw) for the first-line treatment of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
